News | April 25, 2025
We’re working at full force to put Bayer back on a profitable growth path: Bill Anderson, CEO, Bayer
Bayer expects 2025 to be the most difficult year of its turnaround
Bayer expects 2025 to be the most difficult year of its turnaround
A new weapon in the global fight against malaria
Vote expands existing recommendation, which was for all adults aged 75 and older and high-risk adults aged 60 to 74
The discontinuation decision is only on the basis of commercial reasons and is not due to efficacy or safety reasons
This marks a significant milestone in Morepen’s strategic entry into one of the world’s largest pharmaceutical markets
AstraZeneca Pharma India discontinues manufacturing of Imdur
EC decision marks the fourth approval for CAPVAXIVE for pneumococcal vaccination in adults
Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region
New facility will support plans to advance J&J’s portfolio and pipeline of transformational medicines for cancer, immune-mediated and neurological diseases
TB treatment coverage in India increased by 32% in the last eight years from 53% in 2015 to 85% in 2023
Subscribe To Our Newsletter & Stay Updated
